Document:

Document

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

SIXTH AMENDMENT TO AMENDED AND RESTATED
RESEARCH, COLLABORATION AND LICENSE AGREEMENT

This SIXTH AMENDMENT (the “Amendment”), dated August 1, 2021 (the “Sixth Amendment Effective Date”), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.

WHEREAS, the Parties entered into a Research, Collaboration & License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration & License Agreement dated May 28, 2019 (the “Collaboration Agreement”), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, the Third Amendment dated December 23, 2020, the Fourth Amendment also dated December 23, 2021 and the Fifth Amendment dated April 6, 2021 pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications; and

WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.Pursuant to Section 2.5.1, Licensee and Penn have agreed to initiate a Pilot Study for [***]. The Research Plan and timeline for the [***] Pilot Study is contained in the updated Exhibit B to this Sixth Amendment. The Research Program Budget for the [***] Pilot Study program is contained in the updated Exhibit C to this Sixth Amendment. The full amount of the Program Budget will be paid by Licensee within [***] days of the Sixth Amendment Effective Date.

2.This Sixth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Sixth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this Sixth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.

1

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

3.All terms and conditions of the Collaboration Agreement not changed by this Sixth Amendment shall remain in full force and effect. The Parties agree that the this Sixth Amendment is affective retroactively as of the Sixth Amendment Effective Date.

4.Signatures on this Sixth Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.

[Remainder of the page intentionally left blank; signature page follows.]

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.

						
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
	AMICUS    THERAPEUTICS, INC.

	

By:         /s/ John S. Swartley
	

By:     /s/ Jeff Castelli

	Name:  John S. Swartley, PhD
	Name: Jeff Castelli, PhD

	Title:    Associate Vice Provost for Research
and Managing Director, Penn Center for Innovation
	Title: Chief Development Officer

Read and Acknowledged:

By:         /s/ James Wilson
Name:    Dr. James M. Wilson
Title:    Director, Gene Therapy Program

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Exhibit B Research Plan

[***]

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Exhibit C 
Research Program Budget 

[***]Document

PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

EXECUTION COPY CONFIDENTIAL

SEVENTH AMENDMENT TO AMENDED AND RESTATED
RESEARCH, COLLABORATION AND LICENSE AGREEMENT

This SEVENTH AMENDMENT (the “Amendment”), effective as of September 28, 2021 (the “Amendment Date”), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Amicus”). Penn and Amicus may be referred to herein as a “Party” or, collectively, as “Parties”.

WHEREAS, the Parties entered into that certain Amended and Restated Research, Collaboration & License Agreement dated May 28, 2019, as amended through a first amendment dated December 20, 2019, a second amendment dated March 26, 2020, a third amendment dated December 3, 2020, a fourth amendment dated December 23, 2020, a fifth amendment dated April 6, 2021 and a sixth amendment dated August 1, 2021 (collectively, the “Collaboration Agreement”), pursuant to which, among other things, Penn and Amicus are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications; and

WHEREAS, the Parties entered in to that certain Process Development Research & License Agreement dated March 26, 2020 (the “PD Agreement”), pursuant to which, among other things, Penn and Amicus are conducting a research program for the development and/or optimization of manufacturing technology for gene therapy products;
WHEREAS, in conjunction with this Amendment, the Parties are entering into a letter agreement with respect to certain matters dated as of September 28, 2021 (the “Letter Agreement”); and

WHEREAS, the Parties now wish to further amend certain provisions of the Collaboration Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
1.Defined Terms. Capitalized terms used in this Amendment and not defined herein shall have the meaning given to such terms in the Collaboration Agreement, unless otherwise specified herein.

2.Modifications. The Parties agree to amend the Collaboration Agreement by the following revisions:

a.    Section 1.25 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following:

“1.25 “Discovery Program Period” means the period beginning [***] and ending on [***].”

b.The first sentence of Section 3.1.1 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following:

“During the period beginning on the New Effective Date and thereafter for the remainder of the Discovery Program Period, subject to the terms and conditions of this Agreement, Licensee shall pay [***] in research and development funding to Penn to fund the Discovery Program (“Discovery Support Amount”).”
3.Effectiveness; Termination. This Amendment shall automatically terminate without any notice or further action by either Party, and shall be deemed null and void in its entirety, if all of the Transactions described in the second paragraph of the Letter Agreement are not executed and fully consummated on or before [***].
4.No Other Modification. Except as specifically set forth in this Amendment, the terms and conditions of the Collaboration Agreement shall continue in full force and effect and shall apply to this Amendment. This Amendment constitutes the complete and exclusive statement of agreement between the Parties with respect to the subject matter of this Amendment, and supersedes all prior agreements and understandings, and all prior and contemporaneous (oral or written) proposals, understanding, representations, conditions, warranties, covenants and all other communications between the Parties respecting the subject matter hereof. No waiver, modification or amendment of any provision of this Amendment shall be valid or effective unless made in a writing referencing this Amendment and signed by a duly authorized officer of each Party.
5.Miscellaneous. This Amendment may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Amendment, including the signature pages, will be deemed an original. This Amendment shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.

[Remainder of the page intentionally left blank; signature page follows.]

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Agreement as of the Amendment Date.

						
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
	AMICUS THERAPEUTICS, INC.

	

By:    /s/ John S. Swartley
	

By: /s/ John F. Crowley

	Name: John S. Swartley, PhD
	Name: John Crowley

	Title:    Associate Vice Provost for Research
and Managing Director, Penn Center for Innovation
	Title: Chairman and CEO

Read and Acknowledged:

By:    /s/ James M. Wilson
Name:    Dr. James M. Wilson
Title:    Director, Gene Therapy Program

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]